Biophytis (EPA:ALBPS) | WebDisclosure

Basculer en Français

10067	Companies
205809	Keywords
136082	Articles
109134	Press releases

Home
Companies
Biophytis

REGULATED PRESS RELEASE

published on 07/22/2024 at 07:00, 1 year 8 months ago

Biophytis déploie sa stratégie de partenariats et signe deux contrats avec des agents locaux en Asie
Biophytis annonce le déploiement de sa stratégie de partenariats en Asie en signant deux contrats avec des agents locaux pour BIO101 afin d'accélérer son développement sur les marchés clés comme le Japon et la Chine

Biophytis Partenariats Asie Contrats BIO101
REGULATED PRESS RELEASE

published on 07/22/2024 at 07:00, 1 year 8 months ago

Biophytis deploys its partnership strategy and signs two contracts with local agents in Asia
Biophytis implements partnership strategy in Asia with new contracts to advance drug candidate BIO101 in Japan, South Korea, China, and Southeast Asia

Biophytis Asia Contracts Partnership Strategy Drug Candidate BIO101
BRIEF

published on 07/11/2024 at 08:18, 1 year 8 months ago

Biophytis Obtains IND Approval from FDA for Phase 2 Obesity Study

Biophytis FDA Approval Phase 2 Clinical Trial BIO101 Obesity Study
BRIEF

published on 07/11/2024 at 08:18, 1 year 8 months ago

Biophytis obtient l'approbation IND de la FDA pour une étude de phase 2 sur l'obésité

Biophytis Approbation De La FDA Essai Clinique De Phase 2 BIO101 Étude Sur L'obésité
PRESS RELEASE

published on 07/11/2024 at 08:13, 1 year 8 months ago

Biophytis obtains IND approval from the FDA to start its phase 2 OBA study in obesity
Biophytis receives FDA IND approval for phase 2 OBA study in obesity with BIO101 (20-hydroxyecdysone), focusing on muscle strength improvement. Study led by renowned expert Marc-André Cornier

FDA Biophytis Obesity IND Approval OBA Study
PRESS RELEASE

published on 07/11/2024 at 08:13, 1 year 8 months ago

Biophytis obtient l’autorisation IND de la FDA pour démarrer son étude OBA de phase 2 dans l’obésité
Biophytis obtient l'autorisation IND de la FDA pour démarrer son étude OBA de phase 2 dans l'obésité. L'étude vise à mesurer l'amélioration de la force musculaire et la composition corporelle

FDA Biophytis Obésité Autorisation IND Étude OBA
BRIEF

published on 07/11/2024 at 07:06, 1 year 8 months ago

Biophytis obtient l’autorisation IND de la FDA pour une étude de phase 2 dans l’obésité

FDA Biophytis Étude Clinique BIO101 Obésité
BRIEF

published on 07/11/2024 at 07:06, 1 year 8 months ago

Biophytis Receives FDA IND Approval for Phase 2 Obesity Study

Biophytis FDA Approval Phase 2 Study BIO101 Obesity
REGULATED PRESS RELEASE

published on 07/11/2024 at 07:01, 1 year 8 months ago

Biophytis obtient l’autorisation IND de la FDA pour démarrer son étude OBA de phase 2 dans l’obésité
Biophytis obtient l'autorisation IND de la FDA pour lancer l'étude OBA de phase 2 dans l'obésité avec BIO101 (20-hydroxyecdysone), visant à améliorer la force musculaire. Le professeur Marc-André Cornier dirigera l'étude multicentrique aux Etats-Unis

Biophytis BIO101 Obésité Autorisation IND Étude OBA
REGULATED PRESS RELEASE

published on 07/11/2024 at 07:01, 1 year 8 months ago

Biophytis obtains IND approval from the FDA to start its phase 2 OBA study in obesity
Biophytis obtains FDA approval to start phase 2 OBA study in obesity with BIO101 (20-hydroxyecdysone), focusing on muscle strength improvement. Study led by Prof. Marc-André Cornier to start mid-2024 in the USA

Biophytis FDA Approval Obesity Treatment BIO101 Phase 2 OBA Study

Accesswire

Published on 03/23/2026 at 14:05, 6 hours 10 minutes ago

Wellgistics Health Inc. Signs $105,000,000 Letter of Intent to Evaluate Potential Acquisition of Neuritek Therapeutics, Inc. which is Pioneering Innovative Therapies for Neurological and Psychiatric Disorders
Published on 03/23/2026 at 14:00, 6 hours 15 minutes ago

BlackBerry AtHoc Advances Command Center for Faster Response and Tighter Control During Critical Operations
Published on 03/23/2026 at 13:05, 7 hours 10 minutes ago

SouthGobi Announces Disclosable and Connected Transaction Deferral of Payment Obligations Under Convertible Debenture and Amended and Restated Cooperation Agreement
Published on 03/23/2026 at 12:32, 7 hours 43 minutes ago

Sinopec Announced 2025 Annual Results Annual Payout Ratio Reached 81%
Published on 03/23/2026 at 12:30, 7 hours 45 minutes ago

Digi Power X to Announce 2025 Year End Financial Results on March 31st

View all ACCESSWIRE

EQS Group

Published on 03/23/2026 at 19:30, 44 minutes ago

Habitat for Humanity launches Let's Open the Door campaign to drive awareness of global housing need
Published on 03/23/2026 at 19:00, 1 hour 15 minutes ago

PATRIMOINE ET COMMERCE: Déclaration des transactions sur actions propres (Hors contrat de liquidité) réalisées du 16 MARS 2026 au 20 MARS 2026
Published on 03/23/2026 at 18:44, 1 hour 30 minutes ago

Transaction in Own Shares
Published on 03/23/2026 at 18:15, 1 hour 59 minutes ago

ISX Financial EU Plc Announces Corporate Name Change to Xryma Plc
Published on 03/23/2026 at 18:09, 2 hours 5 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares

Les Echos

Published on 03/23/2026 at 19:08, 1 hour 6 minutes ago

Reporting on share buyback transactions carried out between March 16 and March 20, 2026
Published on 03/23/2026 at 19:08, 1 hour 6 minutes ago

Déclaration de rachats d'actions effectués par la Compagnie de Saint-Gobain entre le 16 et le 20 mars 2026
Published on 03/23/2026 at 18:37, 1 hour 37 minutes ago

ALTAREA : Déclaration d’opérations sur actions propres
Published on 03/23/2026 at 17:45, 2 hours 29 minutes ago

ENGIE will build, own and operate its largest onshore wind farm worldwide in Egypt
Published on 03/23/2026 at 17:45, 2 hours 29 minutes ago

En Égypte, ENGIE va construire et exploiter son plus grand parc éolien terrestre au monde

View all LES ECHOS COMFI WIRE